Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta (Aβ) protein aggregates are misfolded assemblies of the amyloid beta peptide, a central molecule in the pathology of Alzheimer’s disease (AD). These aggregates form through a complex process involving monomeric Aβ peptides assembling into soluble oligomers, protofibrils, and eventually insoluble fibrils that deposit as plaques in brain tissue. The aggregation is highly polymorphic and can result in structures with diverse morphologies and toxicities. Soluble oligomeric forms are considered particularly neurotoxic, disrupting synaptic function before plaque deposition occurs. Aggregates mediate cell-to-cell transmission within the brain and induce neuroinflammation by activating microglia.
Antibody-mediated clearance of amyloid beta aggregates, inhibition of amyloid beta aggregation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid Beta Protein Aggregate (Aβ Aggregate).